BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $11,165,000 | -11.6% | 39,312 | +7.9% | 0.02% | -5.6% |
| Q2 2022 | $12,634,000 | -21.5% | 36,447 | -1.9% | 0.02% | -5.3% |
| Q1 2022 | $16,090,000 | +39.9% | 37,157 | +67.2% | 0.02% | +35.7% |
| Q4 2021 | $11,501,000 | +10.3% | 22,229 | +0.1% | 0.01% | 0.0% |
| Q3 2021 | $10,423,000 | +3.2% | 22,200 | -1.0% | 0.01% | 0.0% |
| Q2 2021 | $10,102,000 | +21.7% | 22,435 | +3.2% | 0.01% | +16.7% |
| Q1 2021 | $8,299,000 | -39.5% | 21,730 | -49.7% | 0.01% | +9.1% |
| Q4 2020 | $13,714,000 | +182.5% | 43,186 | +120.4% | 0.01% | +22.2% |
| Q3 2020 | $4,854,000 | -9.3% | 19,593 | -3.3% | 0.01% | -18.2% |
| Q2 2020 | $5,352,000 | +33.6% | 20,269 | -4.0% | 0.01% | +10.0% |
| Q1 2020 | $4,006,000 | -13.0% | 21,124 | +0.7% | 0.01% | +11.1% |
| Q4 2019 | $4,606,000 | +12.2% | 20,985 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $4,106,000 | -6.1% | 20,985 | 0.0% | 0.01% | -10.0% |
| Q2 2019 | $4,375,000 | +5.2% | 20,985 | +0.1% | 0.01% | 0.0% |
| Q1 2019 | $4,160,000 | +37.2% | 20,954 | 0.0% | 0.01% | +25.0% |
| Q4 2018 | $3,032,000 | +145.1% | 20,954 | +245.7% | 0.01% | +166.7% |
| Q3 2018 | $1,237,000 | +38.8% | 6,062 | +0.7% | 0.00% | +50.0% |
| Q2 2018 | $891,000 | -51.0% | 6,019 | -50.0% | 0.00% | 0.0% |
| Q1 2018 | $1,818,000 | +452.6% | 12,032 | +374.6% | 0.00% | +100.0% |
| Q4 2017 | $329,000 | +6.1% | 2,535 | -1.2% | 0.00% | 0.0% |
| Q3 2017 | $310,000 | +2.6% | 2,566 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $302,000 | +16.2% | 2,566 | +0.4% | 0.00% | 0.0% |
| Q1 2017 | $260,000 | -0.4% | 2,557 | +0.7% | 0.00% | 0.0% |
| Q4 2016 | $261,000 | -4.0% | 2,540 | +2.4% | 0.00% | 0.0% |
| Q3 2016 | $272,000 | -3.9% | 2,480 | -1.1% | 0.00% | 0.0% |
| Q2 2016 | $283,000 | – | 2,508 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |